Fusion Pharm Stock Last Dividend Paid
| FSPM Stock | USD 0.0001 0.00 0.000003% |
Fusion Pharm fundamentals help investors to digest information that contributes to Fusion Pharm's financial success or failures. It also enables traders to predict the movement of Fusion Stock. The fundamental analysis module provides a way to measure Fusion Pharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Fusion Pharm stock.
Fusion | Last Dividend Paid |
Fusion Pharm Company Last Dividend Paid Analysis
Fusion Pharm's Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
| Competition |
Based on the recorded statements, Fusion Pharm has a Last Dividend Paid of 0.0. This indicator is about the same for the Consumer Staples Distribution & Retail average (which is currently at 0.0) sector and about the same as Consumer Staples (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Pair Correlation Now
Pair CorrelationCompare performance and examine fundamental relationship between any two equity instruments |
| All Next | Launch Module |
Fusion Fundamentals
| Return On Asset | -1.38 | ||||
| Profit Margin | (1.11) % | ||||
| Operating Margin | (1.24) % | ||||
| Current Valuation | 294.4 K | ||||
| Shares Outstanding | 10.59 M | ||||
| Price To Earning | (0.07) X | ||||
| Price To Sales | 0 X | ||||
| Revenue | 594.4 K | ||||
| Gross Profit | 67.01 K | ||||
| Net Income | (42.08 K) | ||||
| Cash And Equivalents | 1.45 K | ||||
| Total Debt | 1.2 K | ||||
| Current Ratio | 0.73 X | ||||
| Book Value Per Share | (0.07) X | ||||
| Cash Flow From Operations | 239.84 K | ||||
| Earnings Per Share | (0.15) X | ||||
| Beta | 9.72 | ||||
| Market Capitalization | 1.06 K | ||||
| Total Asset | 4.04 K | ||||
| Retained Earnings | (9.11 K) | ||||
| Working Capital | 728 K | ||||
| Current Asset | 1.19 M | ||||
| Current Liabilities | 459 K | ||||
| Net Asset | 4.04 K |
About Fusion Pharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fusion Pharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fusion Pharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fusion Pharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Fusion Pharm Piotroski F Score and Fusion Pharm Altman Z Score analysis. To learn how to invest in Fusion Stock, please use our How to Invest in Fusion Pharm guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Consumer Staples Distribution & Retail space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fusion Pharm. If investors know Fusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fusion Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 0.133 | Return On Assets (1.38) |
The market value of Fusion Pharm is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion Pharm's value that differs from its market value or its book value, called intrinsic value, which is Fusion Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fusion Pharm's market value can be influenced by many factors that don't directly affect Fusion Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fusion Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.